losartan-potassium has been researched along with Parathyroid-Neoplasms* in 3 studies
1 review(s) available for losartan-potassium and Parathyroid-Neoplasms
Article | Year |
---|---|
Paraneoplastic endocrinopathies associated with renal tumors.
Topics: Adenoma; Adrenocorticotropic Hormone; Erythropoietin; Female; Glucagon-Like Peptides; Gonadotropins; Hormones, Ectopic; Humans; Hypercalcemia; Infant; Insulin; Insulin Secretion; Kidney Neoplasms; Male; Middle Aged; Parathyroid Hormone; Parathyroid Neoplasms; Placental Lactogen; Prolactin; Prostaglandins A; Renin | 1979 |
2 other study(ies) available for losartan-potassium and Parathyroid-Neoplasms
Article | Year |
---|---|
The presence of erythropoietin receptor in parathyroid cells.
Effects of erythropoietin on parathyroid cell function has not been studied before.. We aimed to demonstrate whether erythropoietin receptor present in parathyroid cells.. The specimens of normal parathyroid gland, parathyroid adenoma and hyperplasia were retrieved from our pathology archives. The sections were stained immunohistochemically. Quantitative gene expression study was performed for erythropoietin and erythropoietin receptor.. Erythropoietin receptors were detected by immunohistochemical staining and by its gene expression. Its density was higher in normal parathyroid, followed by parathyroid adenoma and hyperplasia.. Erythropoietin receptor is present in normal parathyroid, parathyroid adenoma, and hyperplasia. Topics: Adenoma; Erythropoietin; Gene Expression Regulation; Humans; Hyperplasia; Parathyroid Glands; Parathyroid Neoplasms; Receptors, Erythropoietin | 2007 |
Parathyroid carcinoma associated with polycythemia vera.
A link between hyperparathyroidism and the growth of hematopoietic stem cells is suggested by this report of a parathyroid carcinoma with polycythemia vera. A 56-year-old white woman presented with splenomegaly, a palpable neck mass and hypercalcemia, recurrent six years after resection of a parathyroid tumor. She had pancytosis with a subnormal serum concentration of erythropoietin. Radiographs showed subperiosteal erosions an dosteopenia. Nephrocalcinosis was absent. Bone biopsy showed a decreased cortical width with many intracortical osteoclasts. The cancellous bone area remained normal, but the osteoid area/bone area, osteoblast perimeter and osteoclast perimeter were increased. At surgery, a parathyroid carcinoma was found in the same location operated on previously. As in two other reported cases, postoperative improvement in the hypercalcemia was associated with remission of the blood dyscrasia. A novel finding in this case is that when the hypercalcemia eventually recurred, it was again accompanied by pancytosis. With bisphosphonate therapy, the serum intact parathyroid hormone level increased in response to a decrease in the ionized calcium level, indicating that the cancer was not autonomous. This case suggests that in the presence of the ionized hypercalcemia, the parathyroid tumor may have produced or induced production of a growth factor that can stimulate pancytosis. The differential diagnosis of polycythemia and hypercalcemia should be expanded to include parathyroid tumors in addition to hepatic, adrenal, renal, and ovarian neoplasms. Topics: Bone and Bones; Calcium; Erythropoietin; Female; Follow-Up Studies; Humans; Middle Aged; Parathyroid Hormone; Parathyroid Neoplasms; Polycythemia Vera; Radiography; Radioimmunoassay | 1991 |